Yang Zhou, Feng Xiao, Yu Haoyuan, Lv Lei, Gao Chengli, Liu Wei, Yi Shuhong, Jia Changchang, Fu Binsheng
Department of Hepatic Surgery and Liver Transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-Sen University, Guangzhou, China.
Guangdong Provincial Key Laboratory of Liver Disease Research, Guangdong Province Engineering Laboratory for Transplantation Medicine, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Discov Oncol. 2025 Mar 27;16(1):410. doi: 10.1007/s12672-025-02017-0.
Copy Number Alterations (CNAs)-driven genes have gained attention as potential markers for predicting the response to immune checkpoint blockade in cancer treatment. Among them, VPS72 has emerged as a promising candidate in hepatocellular carcinoma (HCC). However, the relationship between VPS72 and immune infiltration remains unclear.
TIMER analysis was performed to identify immune populations in bulk-RNAseq data. Then, we investigated the relationship between VPS72 and immune infiltration in HCC using diverse data sources, including the TCGA and GEO databases, clinical specimens, and animal models.
Our findings in the immunogenomic and TCGA-LIHC studies revealed significant enrichment of VPS72 among IRG in the altered group. Differential analysis and KEGG pathway analysis further highlighted the involvement of differentially expressed genes (DETs) in pathways related to the T cell receptor signaling pathway. Importantly, TIMER analysis suggested that low expression of VPS72 was associated with high infiltration of CD8 + T cells in multiple publicly available HCC datasets. To validate these findings, we conducted in vivo experiments and observed higher CD8A expression in VPS72-knockdown tumors. Additionally, in our patient cohort, individuals with low VPS72 expression exhibited higher CD8A expression. Furthermore, we identified a co-expression subtype characterized by low VPS72 and high CD8A levels, which showed a more favorable disease-free survival outcome in HCC.
The expression of VPS72 in tumors is associated with the tumor infiltration. VPS72 and CD8A coexpression are prognostic biomarkers in HCC.
拷贝数改变(CNAs)驱动的基因作为预测癌症治疗中免疫检查点阻断反应的潜在标志物受到关注。其中,VPS72已成为肝细胞癌(HCC)中一个有前景的候选基因。然而,VPS72与免疫浸润之间的关系仍不清楚。
进行TIMER分析以识别批量RNA测序数据中的免疫群体。然后,我们使用多种数据源,包括TCGA和GEO数据库、临床标本和动物模型,研究了HCC中VPS72与免疫浸润之间的关系。
我们在免疫基因组学和TCGA-LIHC研究中的发现揭示了改变组中IRG中VPS72的显著富集。差异分析和KEGG通路分析进一步突出了差异表达基因(DETs)参与与T细胞受体信号通路相关的通路。重要的是,TIMER分析表明,在多个公开可用的HCC数据集中,VPS72低表达与CD8 + T细胞的高浸润相关。为了验证这些发现,我们进行了体内实验,并观察到VPS72敲低肿瘤中CD8A表达更高。此外,在我们的患者队列中,VPS72低表达的个体表现出更高的CD8A表达。此外,我们鉴定了一种以VPS72低和CD8A水平高为特征的共表达亚型,其在HCC中显示出更有利的无病生存结果。
肿瘤中VPS72的表达与肿瘤浸润相关。VPS72和CD8A共表达是HCC的预后生物标志物。